AR080204A1 - Procesos para preparar ciclopropilamidas e intermedios asociados con estas - Google Patents

Procesos para preparar ciclopropilamidas e intermedios asociados con estas

Info

Publication number
AR080204A1
AR080204A1 ARP110100485A AR080204A1 AR 080204 A1 AR080204 A1 AR 080204A1 AR P110100485 A ARP110100485 A AR P110100485A AR 080204 A1 AR080204 A1 AR 080204A1
Authority
AR
Argentina
Prior art keywords
formula
compound
pharmaceutically acceptable
preparing
acceptable salt
Prior art date
Application number
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44370080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080204(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR080204A1 publication Critical patent/AR080204A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se exponen procesos para preparar ciclopropilamidas de formula 1 y/o sales farmacéuticamente aceptables de estas e intermedios asociados con estas. Al menos una ciclopropilamida de formula 1 o una sal farmacéuticamente aceptable de esta resulta util para tratar al menos una enfermedad asociada con el receptor H3 de la histamina. Reivindicacion 1: Un compuesto de formula Ia o una sal farmacéuticamente aceptable de este: Reivindicacion 2: Un proceso para preparar un compuesto de acuerdo con la reivindicacion 1, que comprende hacer reaccionar un compuesto de formula IX con (1) una base y un peroxido; y a continuacion (2) una solucion acídica. Reivindicacion 14: Un proceso para preparar un compuesto de formula lb o una sal farmacéuticamente aceptable de este, formula (ib)donde dicho proceso comprende hacer reaccionar un compuesto de formula la con (1) un agente activante y (2) un compuesto de formula IVa o una sal adecuada de este Reivindicacion 18: Un proceso para preparar un compuesto de formula Ic o una sal farmacéuticamente aceptable de este, formula (Ic) donde dicho proceso comprende hacer reaccionar un compuesto de formula la (1) con un agente activante y un compuesto de formula lVb o una sal adecuada de este y (2) una base.
ARP110100485 2010-02-18 2011-02-17 Procesos para preparar ciclopropilamidas e intermedios asociados con estas AR080204A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30558310P 2010-02-18 2010-02-18

Publications (1)

Publication Number Publication Date
AR080204A1 true AR080204A1 (es) 2012-03-21

Family

ID=44370080

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110100486 AR080205A1 (es) 2010-02-18 2011-02-17 Una forma cristalina de un derivado de ciclopropilbenzamida
ARP110100485 AR080204A1 (es) 2010-02-18 2011-02-17 Procesos para preparar ciclopropilamidas e intermedios asociados con estas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110100486 AR080205A1 (es) 2010-02-18 2011-02-17 Una forma cristalina de un derivado de ciclopropilbenzamida

Country Status (19)

Country Link
US (2) US20110201623A1 (es)
EP (2) EP2536685B1 (es)
JP (3) JP2013520414A (es)
KR (2) KR20130004296A (es)
CN (2) CN103168027B (es)
AR (2) AR080205A1 (es)
AU (2) AU2011218491C1 (es)
BR (2) BR112012020629A2 (es)
CA (2) CA2790040A1 (es)
CL (2) CL2012002259A1 (es)
CO (1) CO6592109A2 (es)
ES (1) ES2541857T3 (es)
IL (1) IL221431A (es)
MX (2) MX336333B (es)
NZ (2) NZ601920A (es)
RU (2) RU2012139082A (es)
SG (3) SG182732A1 (es)
TW (2) TWI520945B (es)
WO (2) WO2011102794A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835750B (zh) 2007-08-22 2013-07-17 阿斯利康(瑞典)有限公司 环丙基酰胺衍生物
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US20110201623A1 (en) 2010-02-18 2011-08-18 Uczynski Michael A Crystalline Form Of A Cyclopropyl Benzamide Derivative
JP5746718B2 (ja) * 2010-02-18 2015-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ シクロプロピルアミド誘導体からなる固体形態
FR3003466B1 (fr) * 2013-03-22 2015-08-07 Servier Lab Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques
US9718764B2 (en) * 2013-03-22 2017-08-01 Merck Patent Gmbh Synthetic building blocks for the production of materials for organic electroluminescence devices
CN103342655A (zh) * 2013-07-02 2013-10-09 扬州大学 取代乙二酮双苯胺希夫碱合成取代酰胺的新方法
JP2026000886A (ja) 2024-06-18 2026-01-06 イーライ リリー アンド カンパニー Ｇｉｐ受容体アゴニスト化合物

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (es) 1963-04-04 1900-01-01
NL128365C (es) 1963-11-05
US3449427A (en) 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
DE3418167A1 (de) 1984-05-16 1985-11-21 Bayer Ag, 5090 Leverkusen Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
AU658134B2 (en) 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
EP0435320B1 (en) 1989-12-29 1994-10-05 Banyu Pharmaceutical Co., Ltd. 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives
WO1993003615A1 (en) 1991-08-22 1993-03-04 Monsanto Company Safening herbicidal pyrazolylsulfonylures
DE4131139A1 (de) 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
WO1994020505A1 (en) * 1993-03-12 1994-09-15 The Upjohn Company Crystalline ceftiofur free acid
CN1088062C (zh) 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5859246A (en) 1997-01-30 1999-01-12 Neurogen Corporation 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
WO1998037077A1 (en) 1997-02-24 1998-08-27 Zymogenetics, Inc. Calcitonin mimetics
US6160134A (en) 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
DE69934093T2 (de) 1998-01-27 2007-06-21 Aventis Pharmaceuticals Inc. SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
US6268367B1 (en) 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
US6383520B1 (en) 1998-06-26 2002-05-07 Chugai Seiyaku Kabushiki Kaisha Fine powder of L-α-aminoadipic acid derivative, oral solid preparations containing the same, and method for treatment of bulk powders
NZ512772A (en) 1999-01-08 2003-11-28 Neurogen Corp 1-Phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines useful as dopamine receptor ligands
US6284761B1 (en) * 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2000076993A1 (en) 1999-06-16 2000-12-21 Takeda Chemical Industries, Ltd. Benzazepine derivatives, process for the preparation of the same and uses thereof
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
EP1294685A1 (en) 2000-06-29 2003-03-26 Abbott Laboratories Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
WO2002008221A2 (en) 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
US6888012B2 (en) 2000-12-25 2005-05-03 Ajinomoto Co., Inc. Process for producing optically active halohydrin compound
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US7262185B2 (en) 2001-08-08 2007-08-28 Takeda Chemical Industries Ltd. Benzazepine derivative, process for producing the same, and use
USRE40794E1 (en) 2001-09-26 2009-06-23 Merck & Co., Inc. Crystalline forms of carbapenem antibiotics and methods of preparation
AU2002363236A1 (en) * 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
IL164044A0 (en) 2002-03-22 2005-12-18 Lg Life Sciences Ltd New crystalline forms of (2S)-N-5-Äamino(inino)methylÜ-2-thienylmethyl-1-(2R)-2-Ä(carboxsymethyl)aminoÜ-3,3-diphenylpropanoyl-2-pyrrolidinecarboxamide-nh2o
WO2003103666A2 (en) 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
US20040077618A1 (en) 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040209858A1 (en) 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
JPWO2004046110A1 (ja) 2002-11-15 2006-03-16 アステラス製薬株式会社 メラニン凝集ホルモン受容体拮抗剤
AU2003296993A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
MXPA05011352A (es) 2003-04-23 2005-11-28 Glaxo Group Ltd Derivados de piperazina y su uso para el tratamiento de enfermedades neurologicas y psiquiatricas.
ES2350837T3 (es) 2003-05-01 2011-01-27 Bristol-Myers Squibb Company Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas.
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
CA2549660A1 (en) 2003-12-15 2005-06-30 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
BRPI0418939A (pt) 2004-07-06 2008-04-08 Xenon Pharmaceuticals Inc derivados de nicotinamida e sua utilização como agentes terapêuticos
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
JP5186213B2 (ja) 2004-09-29 2013-04-17 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としての６−ピリジニル−４−ピリミドン誘導体
WO2006040192A1 (en) 2004-10-15 2006-04-20 Glaxo Group Limited Pyrrolidine derivatives as histamine receptors ligands
CN101128435A (zh) 2004-12-27 2008-02-20 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体激动剂用于治疗神经病学及精神病学病症的吡唑酮化合物
CA2595882A1 (en) * 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
JP2008530162A (ja) * 2005-02-15 2008-08-07 グラクソ グループ リミテッド グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
EP1874780A1 (en) 2005-03-25 2008-01-09 Pharmacia & Upjohn Company LLC 4-piperazinylthieno[2,3-d]pyrimidine compounds as platelet aggregation inhibitors
EP1896483A2 (en) 2005-03-28 2008-03-12 Pharmacia & Upjohn Company LLC 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
US20080194590A1 (en) 2005-03-28 2008-08-14 Pfizer Inc 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors
CA2602538A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
JP2009501235A (ja) 2005-07-15 2009-01-15 シェーリング コーポレイション 癌処置において有用なキナゾリン誘導体
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
AU2006275568A1 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
PL1948607T3 (pl) 2005-09-16 2010-09-30 Janssen Pharmaceutica Nv Cyklopropyloaminy jako modulatory receptora histaminowego H3
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
BRPI0618076A2 (pt) 2005-10-31 2011-08-16 Janssen Pharmaceutica Nv processos para a preparação de derivados de ciclopropil-amida
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
US8119668B2 (en) 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
CA2635719A1 (en) 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators
CN101384581B (zh) * 2006-02-17 2013-09-18 弗·哈夫曼-拉罗切有限公司 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物
MX2008011133A (es) 2006-03-01 2008-12-18 Cementech Pty Ltd Matriz para elementos de albañileria y metodo de fabricacion de la misma.
JP2009132621A (ja) 2006-03-13 2009-06-18 Ajinomoto Co Inc シクロプロピルアミド化合物の製造方法
AU2007231594A1 (en) 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
EP2039689A4 (en) 2006-05-26 2011-12-28 Kaneka Corp PROCESS FOR PREPARING OPTICALLY ACTIVE 3-AMINO-2-HYDROXYPROPIONIC ACID CYCLOPROPYLAMID DERIVATIVES AND SALTS THEREOF
CA2655604C (en) 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US20100016293A1 (en) 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
GB0615620D0 (en) * 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
EP2056828A4 (en) * 2006-08-21 2010-06-23 Merck Sharp & Dohme SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS
TW200828371A (en) 2006-09-21 2008-07-01 Matsushita Electric Industrial Co Ltd Chip-type filter
DE102006056526A1 (de) * 2006-11-30 2008-06-05 Archimica Gmbh Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
ATE481395T1 (de) 2007-06-11 2010-10-15 Hoffmann La Roche Cyclohexylderivate
CN101835750B (zh) * 2007-08-22 2013-07-17 阿斯利康(瑞典)有限公司 环丙基酰胺衍生物
WO2009043784A1 (en) * 2007-10-04 2009-04-09 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
DE102008049371A1 (de) 2008-03-06 2009-09-10 Mühlbauer Ag Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür
NZ588634A (en) * 2008-03-20 2012-03-30 Forest Lab Holdings Ltd Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
CA2721303C (en) * 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
WO2010012650A1 (en) 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
CN101462980B (zh) * 2009-01-05 2013-01-09 扬州天辰精细化工有限公司 2，6—二氟苯甲酰胺的工业化生产方法
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US20110201623A1 (en) * 2010-02-18 2011-08-18 Uczynski Michael A Crystalline Form Of A Cyclopropyl Benzamide Derivative
JP5746718B2 (ja) 2010-02-18 2015-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ シクロプロピルアミド誘導体からなる固体形態

Also Published As

Publication number Publication date
IL221431A0 (en) 2012-10-31
EP2536685B1 (en) 2015-04-08
TWI494301B (zh) 2015-08-01
NZ601920A (en) 2014-08-29
TW201144272A (en) 2011-12-16
AU2011218492B2 (en) 2014-11-13
CN103168027B (zh) 2015-08-26
IL221431A (en) 2015-11-30
EP2536685A4 (en) 2013-07-10
AR080205A1 (es) 2012-03-21
US20130172560A1 (en) 2013-07-04
BR112012020782A2 (pt) 2016-05-03
AU2011218491B2 (en) 2014-11-06
MX2012009480A (es) 2012-09-12
JP2013520413A (ja) 2013-06-06
SG183274A1 (en) 2012-09-27
RU2012136148A (ru) 2014-03-27
RU2012139082A (ru) 2014-03-27
MX336333B (es) 2016-01-15
AU2011218492A1 (en) 2012-08-23
TW201136897A (en) 2011-11-01
AU2011218491C1 (en) 2015-05-14
US20110201623A1 (en) 2011-08-18
KR20130004296A (ko) 2013-01-09
EP2536702A1 (en) 2012-12-26
CL2012002259A1 (es) 2012-11-30
CN102869651A (zh) 2013-01-09
AU2011218491A1 (en) 2012-10-04
CA2790040A1 (en) 2011-08-25
CN103168027A (zh) 2013-06-19
SG10201501226VA (en) 2015-04-29
JP2016006103A (ja) 2016-01-14
EP2536685A1 (en) 2012-12-26
ES2541857T3 (es) 2015-07-27
NZ602110A (en) 2014-09-26
KR20130002316A (ko) 2013-01-07
EP2536702A4 (en) 2013-07-10
TWI520945B (zh) 2016-02-11
MX2012009473A (es) 2012-09-12
BR112012020629A2 (pt) 2018-06-19
WO2011102795A1 (en) 2011-08-25
JP2013520414A (ja) 2013-06-06
CL2012002286A1 (es) 2013-01-25
US9012452B2 (en) 2015-04-21
CA2788444A1 (en) 2011-08-25
WO2011102794A1 (en) 2011-08-25
CO6592109A2 (es) 2013-01-02
HK1178142A1 (en) 2013-09-06
SG182732A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
AR116907A2 (es) Derivado de diazabiciclooctano ópticamente activo y proceso para su preparación
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
MX375731B (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
UY32730A (es) Inhibidores de cyp17
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR112014032229A2 (pt) método para produção de 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il) piridina-2-carbonitrila, e intermediários da mesma
BR112014011223A2 (pt) método de tratar uma doença proliferativa
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
ES2541857T3 (es) Procesos para preparar ciclopropilamidas e intermedios asociados con estas

Legal Events

Date Code Title Description
FB Suspension of granting procedure